OS Therapies (NYSEAMERICAN:OSTX) Upgraded by Zacks Research to “Hold” Rating

OS Therapies (NYSEAMERICAN:OSTX) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research note on Friday, October 10th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

OS Therapies Price Performance

OSTX opened at $1.92 on Tuesday. The firm has a 50 day simple moving average of $2.01 and a 200 day simple moving average of $1.90. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00. The company has a market cap of $60.77 million, a price-to-earnings ratio of -2.43 and a beta of -4.10.

Institutional Investors Weigh In On OS Therapies

A number of hedge funds and other institutional investors have recently made changes to their positions in OSTX. CM Management LLC boosted its position in shares of OS Therapies by 172.6% during the first quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $462,000 after buying an additional 189,956 shares during the period. XTX Topco Ltd acquired a new position in OS Therapies during the 2nd quarter worth approximately $63,000. Bridgeway Capital Management LLC acquired a new position in OS Therapies during the 2nd quarter worth approximately $47,000. Finally, Ground Swell Capital LLC bought a new position in shares of OS Therapies during the 3rd quarter worth approximately $40,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.